{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:58:10Z","timestamp":1778903890172,"version":"3.51.4"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T00:00:00Z","timestamp":1614124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000005","name":"United States Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-16-1-0641"],"award-info":[{"award-number":["W81XWH-16-1-0641"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"United States Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-20-1-0362"],"award-info":[{"award-number":["W81XWH-20-1-0362"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA33572"],"award-info":[{"award-number":["P30CA33572"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008307","name":"Beckman Research Institute of City of Hope","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008307","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The incidence of malignant melanoma, a neoplasm of melanocytic cells, is increasing rapidly. The lymph nodes are often the first site of metastasis and can herald systemic dissemination, which is almost uniformly fatal. RLIP, a multi-specific ATP-dependent transporter that is over-expressed in several types of cancers, plays a central role in cancer cell resistance to radiation and chemotherapy. RLIP appears to be necessary for cancer cell survival because both in vitro cell culture and in vivo animal tumor studies show that the depletion or inhibition of RLIP causes selective toxicity to malignant cells. RLIP depletion\/inhibition triggers apoptosis in cancer cells by inducing the accumulation of endogenously formed glutathione-conjugates. In our in vivo studies, we administered RLIP antibodies or antisense oligonucleotides to mice bearing subcutaneous xenografts of SKMEL2 and SKMEL5 melanoma cells and demonstrated that both treatments caused significant xenograft regression with no apparent toxic effects. Anti-RLIP antibodies and antisense, which respectively inhibit RLIP-mediated transport and deplete RLIP expression, showed similar tumor regressing activities, indicating that the inhibition of RLIP transport activity at the cell surface is sufficient to achieve anti-tumor activity. Furthermore, RLIP antisense treatment reduced levels of RLIP, pSTAT3, pJAK2, pSrc, Mcl-1 and Bcl2, as well as CDK4 and cyclin B1, and increased levels of Bax and phospho 5\u2019 AMP-activated protein kinase (pAMPK). These studies indicate that RLIP serves as a key effector in the survival of melanoma cells and is a valid target for cancer therapy. Overall, compounds that inhibit, deplete or downregulate RLIP will function as wide-spectrum agents to treat melanoma, independent of common signaling pathway mutations.<\/jats:p>","DOI":"10.1093\/carcin\/bgab016","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T21:00:34Z","timestamp":1613768434000},"page":"742-752","source":"Crossref","is-referenced-by-count":5,"title":["RLIP depletion induces apoptosis associated with inhibition of JAK2\/STAT3 signaling in melanoma cells"],"prefix":"10.1093","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6415-8160","authenticated-orcid":false,"given":"Sharad S","family":"Singhal","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Beckman Research Institute, City of Hope Comprehensive Cancer Center and National Medical Center, Duarte, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atish","family":"Mohanty","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Beckman Research Institute, City of Hope Comprehensive Cancer Center and National Medical Center, Duarte, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prakash","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Beckman Research Institute, City of Hope Comprehensive Cancer Center and National Medical Center, Duarte, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Horne","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Beckman Research Institute, City of Hope Comprehensive Cancer Center and National Medical Center, Duarte, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Awasthi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology and Oncology, Texas Tech University Health Sciences Center, Lubbock, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Salgia","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Beckman Research Institute, City of Hope Comprehensive Cancer Center and National Medical Center, Duarte, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,2,24]]},"reference":[{"key":"2022022401090088300_CIT0001","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1038\/s41467-020-15546-9","article-title":"Pre-clinical modeling of cutaneous melanoma","volume":"11","author":"Rebecca","year":"2020","journal-title":"Nat. Commun."},{"key":"2022022401090088300_CIT0002","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jid.2020.03.943","article-title":"Treatment of advanced melanoma in 2020 and beyond","volume":"141","author":"Jenkins","year":"2021","journal-title":"J. Invest. Dermatol."},{"key":"2022022401090088300_CIT0003","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"2022022401090088300_CIT0004","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/sj.bjc.6604891","article-title":"Integrating BRAF\/MEK inhibitors into combination therapy for melanoma","volume":"100","author":"Smalley","year":"2009","journal-title":"Br. J. Cancer"},{"key":"2022022401090088300_CIT0005","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nature04304","article-title":"BRAF mutation predicts sensitivity to MEK inhibition","volume":"439","author":"Solit","year":"2006","journal-title":"Nature"},{"key":"2022022401090088300_CIT0006","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1158\/1535-7163.MCT-08-0431","article-title":"Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas","volume":"7","author":"Smalley","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"2022022401090088300_CIT0007","first-page":"3003","article-title":"Co-targeting survival signaling pathways in cancer","volume":"118","author":"Grant","year":"2007","journal-title":"J. Clin. Invest."},{"key":"2022022401090088300_CIT0008","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.coph.2006.01.009","article-title":"Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer","volume":"6","author":"Modok","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"key":"2022022401090088300_CIT0009","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.bcp.2007.12.001","article-title":"Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1\u00ae","volume":"75","author":"Robey","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"2022022401090088300_CIT0010","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1517\/17425255.4.2.205","article-title":"Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges","volume":"4","author":"Shukla","year":"2008","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"2022022401090088300_CIT0011","doi-asserted-by":"crossref","first-page":"9327","DOI":"10.1021\/bi992964c","article-title":"Novel function of human RLIP76: ATP-dependent transport of glutathione conjugates and doxorubicin","volume":"39","author":"Awasthi","year":"2000","journal-title":"Biochemistry"},{"key":"2022022401090088300_CIT0012","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/ijc.11260","article-title":"Transport of glutathione conjugates and chemotherapeutic drugs by RLIP76 (RALBP1): a novel link between G-protein and tyrosine kinase signaling and drug resistance","volume":"106","author":"Awasthi","year":"2003","journal-title":"Int. J. Cancer"},{"key":"2022022401090088300_CIT0013","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1158\/1078-0432.CCR-08-0145","article-title":"RLIP76 and Cancer","volume":"14","author":"Awasthi","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"2022022401090088300_CIT0014","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ijrobp.2008.06.1497","article-title":"RLIP76 in defense of radiation poisoning","volume":"72","author":"Singhal","year":"2008","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"2022022401090088300_CIT0015","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/1523-1747.ep12313403","article-title":"Glutathione and related enzymes in tumor progression and metastases of human melanoma","volume":"105","author":"Schadendorf","year":"1995","journal-title":"J. Invest. Dermatol."},{"key":"2022022401090088300_CIT0016","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1158\/0008-5472.CAN-05-3534","article-title":"Regression of melanoma in a murine model by RLIP76 depletion","volume":"66","author":"Singhal","year":"2006","journal-title":"Cancer Res."},{"key":"2022022401090088300_CIT0017","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1158\/0008-5472.CAN-10-3852","article-title":"6-Bromoindirubin-3\u2032-oxime inhibits JAK\/STAT3 signaling and induces apoptosis of human melanoma cells","volume":"71","author":"Liu","year":"2011","journal-title":"Cancer Res."},{"key":"2022022401090088300_CIT0018","doi-asserted-by":"crossref","first-page":"13885","DOI":"10.1039\/C4CC04498C","article-title":"Virtual screening and optimization of Type II inhibitors of JAK2 from a natural product library","volume":"50","author":"Ma","year":"2014","journal-title":"Chem. Commun. (Camb)."},{"key":"2022022401090088300_CIT0019","doi-asserted-by":"crossref","first-page":"e49306","DOI":"10.1371\/journal.pone.0049306","article-title":"Spirooxindole derivative SOID-8 induces apoptosis associated with inhibition of JAK2\/STAT3 signaling in melanoma cells","volume":"7","author":"Tian","year":"2012","journal-title":"PLoS One"},{"key":"2022022401090088300_CIT0020","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1093\/emboj\/cdf351","article-title":"Cytoplasmic transport of Stat3 by receptor-mediated endocytosis","volume":"21","author":"Bild","year":"2002","journal-title":"EMBO J."},{"key":"2022022401090088300_CIT0021","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.V58.4.733.733","article-title":"Enzymatic conjugation of erythrocyte glutathione with 1-chloro-2,4-dinitrobenzene: the fate of glutathione conjugate in erythrocytes and the effect of glutathione depletion on hemoglobin","volume":"58","author":"Awasthi","year":"1981","journal-title":"Blood"},{"key":"2022022401090088300_CIT0022","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1172\/JCI117102","article-title":"Adenosine-triphosphate-dependent transport of doxorubicin, daunomyicn, and vinblastine in human tissues by a mechanism distinct from the P-glycoprotein","volume":"93","author":"Awasthi","year":"1994","journal-title":"J. Clin. Invest."},{"key":"2022022401090088300_CIT0023","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/carcin\/bgs401","article-title":"RLIP76 is overexpressed in human glioblastomas and is required for proliferation, tumorigenesis and suppression of apoptosis","volume":"34","author":"Wang","year":"2013","journal-title":"Carcinogenesis"},{"key":"2022022401090088300_CIT0024","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1593\/neo.101080","article-title":"RalBP1 is necessary for metastasis of human cancer cell lines","volume":"12","author":"Zhong","year":"2010","journal-title":"Neoplasia"},{"key":"2022022401090088300_CIT0025","first-page":"2105","article-title":"RLIP76 expression as a prognostic marker of breast cancer","volume":"19","author":"Wang","year":"2015","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"2022022401090088300_CIT0026","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/ijc.20516","article-title":"RLIP76-mediated transport of leukotriene C4 in cancer cells: implications in drug-resistance","volume":"112","author":"Sharma","year":"2004","journal-title":"Int. J. Cancer"},{"key":"2022022401090088300_CIT0027","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/0006-2952(96)00450-9","article-title":"Multidrug-resistance mediated by the multidrug-resistance protein (MRP) gene","volume":"52","author":"Lautier","year":"1996","journal-title":"Biochem. Pharmacol."},{"key":"2022022401090088300_CIT0028","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev.bi.62.070193.002125","article-title":"Biochemistry of multidrug-resistance mediated by the multidrug-transporter","volume":"62","author":"Gottesman","year":"1993","journal-title":"Annu. Rev. Biochem."},{"key":"2022022401090088300_CIT0029","first-page":"713","article-title":"Role of RLIP76 in lung cancer doxorubicin-resistance: Doxorubicin-transport in lung cancer by RLIP76","volume":"22","author":"Awasthi","year":"2003","journal-title":"Int. J. Oncol."},{"key":"2022022401090088300_CIT0030","doi-asserted-by":"crossref","first-page":"15420","DOI":"10.1074\/jbc.274.22.15420","article-title":"Monoclonal-antibodies that inhibit the transport function of the 190-kDa multidrug-resistance protein, MRP. Localization of their epitopes to the nucleotide-binding-domains of the protein","volume":"274","author":"Hipfner","year":"1999","journal-title":"J. Biol. Chem."},{"key":"2022022401090088300_CIT0031","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1006\/bbrc.1996.5970","article-title":"Functional modulation of ATPase of P-glycoprotein by C219, a monoclonal-antibody against P-glycoprotein","volume":"230","author":"Kokubu","year":"1997","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2022022401090088300_CIT0032","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1158\/0008-5472.CAN-06-4124","article-title":"Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76 (Ral-binding protein 1)","volume":"67","author":"Singhal","year":"2007","journal-title":"Cancer Res."},{"key":"2022022401090088300_CIT0033","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.bcp.2008.11.013","article-title":"Regression of prostate cancer xenografts by RLIP76 depletion","volume":"77","author":"Singhal","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"2022022401090088300_CIT0034","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.1158\/0008-5472.CAN-08-3521","article-title":"RLIP76: a target for kidney cancer therapy","volume":"69","author":"Singhal","year":"2009","journal-title":"Cancer Res."},{"key":"2022022401090088300_CIT0035","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1158\/1940-6207.CAPR-11-0025","article-title":"Targeting p53 null neuroblastomas through RLIP76","volume":"4","author":"Singhal","year":"2011","journal-title":"Cancer Prev. Res."},{"key":"2022022401090088300_CIT0036","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nrc1275","article-title":"The STATs of cancer \u2013 new molecular targets come of age","volume":"4","author":"Yu","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"2022022401090088300_CIT0037","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: a leading role for STAT3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"2022022401090088300_CIT0038","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1038\/sj.onc.1203594","article-title":"IL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled","volume":"19","author":"Reddy","year":"2000","journal-title":"Oncogene"},{"key":"2022022401090088300_CIT0039","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10555-005-1580-1","article-title":"Targeting STAT3 affects melanoma on multiple fronts","volume":"24","author":"Kortylewski","year":"2005","journal-title":"Cancer Metastasis Rev."},{"key":"2022022401090088300_CIT0040","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bbrc.2010.06.052","article-title":"AMP-activated kinase (AMPK)-generated signals in malignant melanoma cell growth and survival","volume":"398","author":"Woodard","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2022022401090088300_CIT0041","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1158\/1078-0432.CCR-04-1752","article-title":"Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells","volume":"12","author":"Gritsko","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"2022022401090088300_CIT0042","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1128\/MCB.06291-11","article-title":"The RalB small GTPase mediates formation of invadopodia through a GTPase-activating protein-independent function of the RalBP1\/RLIP76 effector","volume":"32","author":"Neel","year":"2012","journal-title":"Mol. Cell. Biol."},{"key":"2022022401090088300_CIT0043","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1475-2867-11-22","article-title":"Different metastasis promotive potency of small G-proteins RalA and RalB in in vivo hamster tumor model","volume":"11","author":"Rybko","year":"2011","journal-title":"Cancer Cell Int."},{"key":"2022022401090088300_CIT0044","doi-asserted-by":"crossref","first-page":"694","DOI":"10.4161\/cbt.20087","article-title":"Overexpression of RalBP1 in colorectal cancer is an independent predictor of poor survival and early tumor relapse","volume":"13","author":"Mollberg","year":"2012","journal-title":"Cancer Biol. Ther."},{"key":"2022022401090088300_CIT0045","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1158\/0008-5472.CAN-12-0468","article-title":"RALBP1\/RLIP76 depletion in mice suppresses tumor growth by inhibiting tumor neovascularization","volume":"72","author":"Lee","year":"2012","journal-title":"Cancer Res."},{"key":"2022022401090088300_CIT0046","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/1535-7163.MCT-10-0699","article-title":"Glutathione-conjugate transport by RLIP76 is required for clathrin-dependent endocytosis and chemical carcinogenesis","volume":"10","author":"Singhal","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"2022022401090088300_CIT0047","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/mc.22894","article-title":"2\u2032-Hydroxyflavanone inhibits in vitro and in vivo growth of breast cancer cells by targeting RLIP76","volume":"57","author":"Singhal","year":"2018","journal-title":"Mol. Carcinog."},{"key":"2022022401090088300_CIT0048","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.canlet.2019.01.023","article-title":"RLIP inhibition suppresses breast-to-lung metastasis","volume":"447","author":"Singhal","year":"2019","journal-title":"Cancer Lett."},{"key":"2022022401090088300_CIT0049","doi-asserted-by":"crossref","first-page":"6022","DOI":"10.1158\/0008-5472.CAN-05-0968","article-title":"RLIP76 is a major determinant of radiation sensitivity","volume":"65","author":"Awasthi","year":"2005","journal-title":"Cancer Res."},{"key":"2022022401090088300_CIT0050","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.3390\/cancers11101556","article-title":"Topical 2\u2032-hydroxyflavanone for cutaneous melanoma","volume":"11","author":"Bose","year":"2019","journal-title":"Cancers"},{"key":"2022022401090088300_CIT0051","doi-asserted-by":"crossref","first-page":"188337","DOI":"10.1016\/j.bbcan.2020.188337","article-title":"RLIP controls receptor-ligand signaling by regulating clathrin-dependent endocytosis","volume":"1873","author":"Singhal","year":"2020","journal-title":"Biochim. Biophys. Acta. Rev. Cancer"},{"key":"2022022401090088300_CIT0052","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/carcin\/bgaa048","article-title":"Targeting RLIP with CRISPR\/Cas9 controls tumor growth","volume":"42","author":"Singhal","year":"2021","journal-title":"Carcinogenesis"}],"container-title":["Carcinogenesis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/carcin\/advance-article-pdf\/doi\/10.1093\/carcin\/bgab016\/36893508\/bgab016.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/carcin\/article-pdf\/42\/5\/742\/41162039\/bgab016.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/carcin\/article-pdf\/42\/5\/742\/41162039\/bgab016.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T01:09:54Z","timestamp":1645664994000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/carcin\/article\/42\/5\/742\/6148863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,24]]},"references-count":52,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,2,24]]},"published-print":{"date-parts":[[2021,5,28]]}},"URL":"https:\/\/doi.org\/10.1093\/carcin\/bgab016","relation":{},"ISSN":["0143-3334","1460-2180"],"issn-type":[{"value":"0143-3334","type":"print"},{"value":"1460-2180","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5,1]]},"published":{"date-parts":[[2021,2,24]]}}}